Manufacturing Agreement Sample Contracts

Traqer Corp – Patented Products Licensing and Manufacturing Agreement (English Translation) Donggao International Group Co., Ltd. Guangzhou Donggao New Material Co., Ltd. Patented Products Licensing and Manufacturing Agreement (September 28th, 2018)

The Demander has investigated the Supplier's premises, equipment, personnel and other conditions. The Demander has determined that the Supplier has the production conditions and qualifications required by the Demander and has delivered the patent authorized by the Demander to the Supplier in writing, so that the Supplier is entitled to the licensed / entrusted production of the patented products and can produce them legally but will not sell or use such products. Whereas the Demander intends to license / entrust the Supplier to produce the Demander's patented products and both parties reach a consensus through friendly negotiation, both parties enter into this Contract according to the General Civil Law of the People's Republic of China, the Contract Law of the People's Republic of China, the Patent Law of the People's Republic of China and other laws and regulations and on the basis of voluntariness, equality and mutual benefit on June 27, 2018:

SI-BONE, Inc. – Quality and Manufacturing Agreement by and Between CEP Bio-Coat, LLC Dba Orchid Detroit and SI-BONE, Inc. (September 20th, 2018)
SI-BONE, Inc. – Quality and Manufacturing Agreement by and Between CEP Bio-Coat, LLC Dba Orchid Detroit and SI-BONE, Inc. (July 31st, 2018)
Vaccinex, Inc. – CONFIDENTIAL GPEx(r) DEVELOPMENT AND MANUFACTURING AGREEMENT (July 9th, 2018)

This GPEx(r) Development and Manufacturing Agreement (Agreement) is made as of January 13, 2010 (Effective Date), by and between Vaccinex, Inc., a with a place of business at 1895 Mt. Hope Avenue, Rochester, NY 14620, USA (Vaccinex) and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (Catalent).

Sonos Inc – Manufacturing Agreement Between Sonos, Inc. And IAC (July 6th, 2018)

This Manufacturing Agreement, including the Exhibits (Agreement), effective as of September 4, 2014 (Effective Date), is by and between Sonos, Inc., a Delaware corporation, having its principal offices at 223 E. De La Guerra Street, Santa Barbara, CA, 93101, USA (Sonos), and Inventec Appliances Corporation, having principal offices at 37, Wugong 5th Road, Wugu District, New Taipei City, 24890, Taiwan, R.O.C. (IAC).

Forty Seven, Inc. – Assigned Capacity and Manufacturing Agreement (The Agreement) (June 18th, 2018)

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Magenta Therapeutics, Inc. – Master Development and Manufacturing Agreement (June 18th, 2018)

This Master Development and Manufacturing Agreement (including all appendices hereto, this Agreement) is entered into as of February 13, 2018 (the Effective Date) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (Magenta), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (Bachem). Magenta and Bachem may be referred to individually as a Party or collectively as the Parties.

Forty Seven, Inc. – Assigned Capacity and Manufacturing Agreement (The Agreement) (June 1st, 2018)

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Magenta Therapeutics, Inc. – Master Development and Manufacturing Agreement (May 24th, 2018)

This Master Development and Manufacturing Agreement (including all appendices hereto, this Agreement) is entered into as of February 13, 2018 (the Effective Date) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (Magenta), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (Bachem). Magenta and Bachem may be referred to individually as a Party or collectively as the Parties.

Insys Therapeutics Inc. – Amendment No. 5 to Manufacturing Agreement (May 10th, 2018)
Manufacturing Agreement (May 4th, 2018)

This Manufacturing Agreement ("Agreement") is made and entered into as of the 20th day of March, 2018 (the "Effective Date") by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300, Ewing, NJ 08628 ("Antares"), and AMAG Pharmaceuticals, Inc., a Delaware corporation, with a corporate address at 1100 Winter Street, Waltham, MA 02451 ("AMAG"). Antares and AMAG are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Forty Seven, Inc. – Assigned Capacity and Manufacturing Agreement (The Agreement) (April 30th, 2018)

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Electrameccanica Vehicles Corp. – Manufacturing Agreement (April 19th, 2018)

ELECTRAMECCANICA VEHICLES CORP., an entity incorporated under the laws of the Province of British Columbia, Canada, with an address of Suite 102 East 1st Avenue, Vancouver, British Columbia, Canada, V5T 1A4 ("EMV");

Vaccinex, Inc. – CONFIDENTIAL GPEx(r) DEVELOPMENT AND MANUFACTURING AGREEMENT (April 13th, 2018)

This GPEx(r) Development and Manufacturing Agreement (Agreement) is made as of January 13, 2010 (Effective Date), by and between Vaccinex, Inc., a with a place of business at 1895 Mt. Hope Avenue, Rochester, NY 14620, USA (Vaccinex) and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (Catalent).

Adma Biologics, Inc. – Amendment #2 to the Manufacturing Agreement (March 29th, 2018)

This Amendment #2 to the Manufacturing Agreement (this "Amendment #2") is made effective as of August 1, 2016 ("Effective Date"), by and between Biotest Pharmaceuticals Corporation, a Delaware corporation, having a place of business at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487 USA ("BPC") and Sanofi Pasteur S.A., a company existing and organized under the laws of France ("Sanofi Pasteur"), having its registered head office at 2, avenue Pont Pasteur, 69007, Lyon, France.

Adma Biologics, Inc. – Amendment #3 to the Manufacturing Agreement (March 29th, 2018)

This Amendment #3 to the Manufacturing Agreement (this "Amendment #3") is made effective as of December 21, 2017 ("Amendment Effective Date"), by and between ADMA BioManufacturing, LLC, a Delaware limited liability company, having a place of business at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487 USA ("ADMA") and Sanofi Pasteur S.A., a company existing and organized under the laws of France ("Sanofi Pasteur"), having its registered head office at 14, espace Henry Vallee, 69007, Lyon, France.

Adma Biologics, Inc. – Manufacturing Agreement (March 29th, 2018)

THIS MANUFACTURING AGREEMENT (this "Agreement") is effective as of September 30, 2011 (the "Effective Date") by and between Biotest Pharmaceuticals Corporation, a Delaware corporation ("BPC"), having its principal place of business at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487, and Sanofi Pasteur S.A., a company existing and organized under the laws of France ("Sanofi Pasteur"), having its registered head office at 2, avenue Pont Pasteur, 69007, Lyon, France.

Magenta Therapeutics, Inc. – Master Development and Manufacturing Agreement (March 28th, 2018)

This Master Development and Manufacturing Agreement (including all appendices hereto, this Agreement) is entered into as of February 13, 2018 (the Effective Date) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (Magenta), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (Bachem). Magenta and Bachem may be referred to individually as a Party or collectively as the Parties.

Coca-Cola Bottling Co. Consolidated – Second Amendment to Regional Manufacturing Agreement (February 28th, 2018)

This Second Amendment to Regional Manufacturing Agreement (this "Amendment") is entered into on October 2, 2017 (the "Effective Date"), by and between The Coca-Cola Company, a Delaware corporation ("Company"), and Coca-Cola Bottling Co. Consolidated, a Delaware corporation ("Bottler"). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Agreement.

Sonos Inc – Manufacturing Agreement Between Sonos, Inc. And IAC (February 9th, 2018)

This Manufacturing Agreement, including the Exhibits (Agreement), effective as of September 4, 2014 (Effective Date), is by and between Sonos, Inc., a Delaware corporation, having its principal offices at 223 E. De La Guerra Street, Santa Barbara, CA, 93101, USA (Sonos), and Inventec Appliances Corporation, having principal offices at 37, Wugong 5th Road, Wugu District, New Taipei City, 24890, Taiwan, R.O.C. (IAC).

Electrameccanica Vehicles Corp. – Manufacturing Agreement (February 1st, 2018)

ELECTRAMECCANICA VEHICLES CORP., an entity incorporated under the laws of the Province of British Columbia, Canada, with an address of Suite 102 East 1st Avenue, Vancouver, British Columbia, Canada, V5T 1A4 ("EMV");

Quanterix Corp – Supply and Manufacturing Agreement (November 9th, 2017)

This SUPPLY AND MANUFACTURING AGREEMENT (this Agreement) is made by and between STRATEC Biomedical AG (formerly STRATEC Biomedical Systems AG), a stock corporation formed under the laws of the Federal Republic of Germany, having its principal place of business at Gewerbestrasse 37, D-75217 Birkenfeld-Graefenhausen, Germany (STRATEC) and Quanterix Corporation, One Kendall Square, Suite B14201, Cambridge, MA 02139 (hereinafter referred to as QTX, and both STRATEC and QTX are referred to as the Parties). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Development Agreement (as defined below).

Flamel Technologies S.A. – Manufacturing Agreement (November 9th, 2017)

This Manufacturing Agreement (the "Agreement") is made as of this 14th day of July, 2014 (the "Effective Date") by and between Serenity Pharmaceuticals, a corporation organized under the laws of the State of Delaware with its principal place of business at 105 Hawk Court, Milford, Pennsylvania 18337 (hereinafter referred to as "SERENITY") and DPT Lakewood LLC, a corporation organized under the laws of the State of Delaware with a place of business at 1200 Paco Way, Lakewood, New Jersey, 08701, individually and on behalf of its Affiliates (hereinafter collectively referred to as "DPT"). SERENITY and DPT shall hereinafter be individually referred to as a "Party" and collectively as the "Parties."

Quanterix Corp – First Amendment to Supply and Manufacturing Agreement (November 9th, 2017)

THIS AMENDMENT (the Amendment) is made and entered into effective as of October 17, 2013, by and between QUANTERIX CORPORATION, a company organized and existing pursuant to the laws of Delaware, U.S.A. (QTX), and STRATEC BIOMEDICAL AG, a company organized and existing pursuant to the laws of the Federal Republic of Germany (STRATEC). QTX and STRATEC each may be referred to herein individually as a Party, or collectively as the Parties.

Endo International plc – Fifth Amendment to Supply and Manufacturing Agreement (November 9th, 2017)

THIS FIFTH AMENDMENT, dated as of this 19th day of July, 2017, is by and among Teikoku Seiyaku Co., Ltd./Teikoku Pharma USA, Inc. (collectively, "TEIKOKU") and ENDO VENTURES LIMITED ("ENDO") and ENDO PHARMACEUTICALS INC. ("EPI").

Hancock Jaffe Laboratories, Inc. – Development and Manufacturing Agreement (November 6th, 2017)

This Development and Manufacturing Agreement (the "Agreement") is made and entered into on this 1st day of February, 2013, by and between Hancock Jaffe Laboratories Aesthetics, Inc. ("HJLA"), a Delaware corporation having a business address at 70 Doppler, Irvine, California and Hancock Jaffe Laboratories, Inc. (the "Company"), a Delaware corporation.

SpineEx, Inc. – License and Manufacturing Agreement (October 13th, 2017)

This License and Manufacturing Agreement ("Agreement") is entered into this 13th day of July, 2017 ("Effective Date"), by and between JB Medical Development, LLC, dba MD3, LLC, a Florida_ limited liability company, with its principal place of business located at 3650 Coral Ridge Drive, Suite 107, Coral Springs, FL 33065 ("MD3"), and SpineEX, Inc., a Delaware corporation, with a place of business located at 48531 Warm Springs Blvd., Suite 416, Fremont, CA 94539 (defined below) ("SpineEX"). SpineEX and MD3 are referred to in this Agreement each as "Party" and collectively as the "Parties."

Restoration Robotics Inc – Manufacturing Agreement for Consumables (September 1st, 2017)

This MANUFACTURING AGREEMENT FOR CONSUMABLES (hereinafter referred to as Agreement) is made and entered into as of the 1st day of April 2016, (hereinafter Effective Date), by and between Evolve Manufacturing Technologies Inc. (hereinafter Seller) having a principal place of business at 47300 Bayside Parkway, Fremont, CA 94538 and Restoration Robotics, Inc., (hereinafter Buyer), having a principal place of business at 128 Baytech Drive, San Jose, CA 95134. Seller and Buyer are collectively referred to herein as the Parties and individually as a Party.

Restoration Robotics Inc – Manufacturing Agreement for Systems (September 1st, 2017)

This MANUFACTURING AGREEMENT FOR SYSTEMS (hereinafter referred to as Agreement) is made and entered into as of the 1st day of MARCH 2016, (hereinafter Effective Date), by and between Evolve Manufacturing Technologies Inc. (hereinafter Seller) having a principal place of business at 47300 Bayside Parkway, Fremont, CA 94538 and Restoration Robotics, Inc., (hereinafter Buyer), having a principal place of business at 128 Baytech Drive, San Jose, CA 95134. Seller and Buyer are collectively referred to herein as the Parties and individually as a Party.

Quanterix Corp – First Amendment to Supply and Manufacturing Agreement (August 17th, 2017)

THIS AMENDMENT (the Amendment) is made and entered into effective as of October 17, 2013, by and between QUANTERIX CORPORATION, a company organized and existing pursuant to the laws of Delaware, U.S.A. (QTX), and STRATEC BIOMEDICAL AG, a company organized and existing pursuant to the laws of the Federal Republic of Germany (STRATEC). QTX and STRATEC each may be referred to herein individually as a Party, or collectively as the Parties.

Quanterix Corp – Supply and Manufacturing Agreement (August 17th, 2017)

This SUPPLY AND MANUFACTURING AGREEMENT (this Agreement) is made by and between STRATEC Biomedical AG (formerly STRATEC Biomedical Systems AG), a stock corporation formed under the laws of the Federal Republic of Germany, having its principal place of business at Gewerbestrasse 37, D-75217 Birkenfeld-Graefenhausen, Germany (STRATEC) and Quanterix Corporation, One Kendall Square, Suite B14201, Cambridge, MA 02139 (hereinafter referred to as QTX, and both STRATEC and QTX are referred to as the Parties). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Development Agreement (as defined below).

Commercial Manufacturing Agreement (August 9th, 2017)

THIS MANUFACTURING AGREEMENT (the "Agreement") is made and entered into this 18th day of September, 2015 (the "Effective Date"), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 ("AAIPharma") and Marathon Pharmaceuticals, LLC having a place of business at 1033 Skokie Blvd., Suite 600, Northbrook, IL 60062 USA ("Company"). AAIPharma and Company, as used herein, may be referred to, collectively, as "Parties" and individually as a "Party".

Coca-Cola Bottling Co. Consolidated – First Amendment to Regional Manufacturing Agreement (August 8th, 2017)

This First Amendment to Regional Manufacturing Agreement (this "Amendment") is entered into on April 28, 2017 (the "Effective Date"), by and between The Coca-Cola Company, a Delaware corporation ("Company"), and Coca-Cola Bottling Co. Consolidated, a Delaware corporation ("Bottler"). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Agreement (as hereinafter defined and as amended hereby).

First Amendment to Master Assay Development, Commercialization and Manufacturing Agreement (August 8th, 2017)

First Amendment to Master Assay Development, Commercialization and Manufacturing Agreement ("Amendment"), dated June 14, 2017, is by and between HTG Molecular Diagnostics, Inc., a corporation organized under the laws of the State of Delaware, U.S., with a place of business at 3430 E. Global Loop, Tucson, AZ 85706 and QIAGEN Manchester Limited, a corporation organized under the laws of the United Kingdom, with a place of business at Skelton House, Lloyd Street North, Manchester, UK.

Supply and Manufacturing Agreement (August 4th, 2017)

This Amended and Restated Supply and Manufacturing Agreement (the "Supply Agreement") is made effective as of the 1st day of April, 2017 (the "Effective Date") by and between Cerus Corporation ("Cerus"), a Delaware corporation, having its principal place of business at 2550 Stanwell Drive, Concord, CA 94520, and Porex Corporation ("Porex"), a Delaware corporation, having its principal place of business at 500 Bohannon Road, Fairburn, GA 30213. (Cerus and Porex are each individually referred to in this Supply Agreement as a "Party" and, collectively, as the "Parties").